Get started
Author

Audrey Gill

A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models
2023 · Bettina van Lengerich, Lihong Zhan, et al. · Nature Neuroscience · 230
PDF
CD98hc is a target for brain delivery of biotherapeutics
2023 · Kylie S. Chew, Robert C. Wells, et al. · Nature Communications · 97
PDF
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer
2020 · Joseph D. Schonhoft, Jimmy L. Zhao, et al. · Cancer Research · 39
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
2021 · Landon C. Brown, Susan Halabi, et al. · Clinical Cancer Research · 36
Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
2020 · David Lu, Rachel Krupa, et al. · Journal of Circulating Biomarkers · 16
PDF
Uncovering the cellular capacity for intensive and specific feedback self-control of the argonautes and MicroRNA targeting activity
2020 · Degeng Wang, Tingzeng Wang, et al. · Nucleic Acids Research · 15
PDF
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response
2023 · Ernie Yulyaningsih, Jung H. Suh, et al. · eLife · 14
PDF
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
2021 · Johann S. De Bono, Klaus Pantel, et al. · Journal of Clinical Oncology · 4
Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane.
2020 · Howard I. Scher, Adam Jendrisak, et al. · Journal of Clinical Oncology · 3
DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response
2024 · Ernie Yulyaningsih, Jung H. Suh, et al. · eLife · 2
Author Correction: CD98hc is a target for brain delivery of biotherapeutics
2023 · Kylie S. Chew, Robert C. Wells, et al. · Nature Communications · 2
PDF
Author response: DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response
2024 · Ernie Yulyaningsih, Jung H. Suh, et al. · eLife · 1
Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.
2020 · Shruti U. Gandhy, Fatima Karzai, et al. · Journal of Clinical Oncology · 1
Preliminary results from phase I/II, first-in-human, open-label study of DNL126 in children with mucopolysaccharidosis type IIIA (MPS IIIA)
2026 · Elizabeth Jalazo, John Bernat, et al. · Molecular Genetics and Metabolism
Author response: DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response
2024 · Ernie Yulyaningsih, Jung H Suh, et al. · eLife
ETV:SGSH, a brain-penetrant enzyme transport vehicle for SGSH, improves lysosomal and microglial morphology, degeneration and cognitive behavior in MPS IIIA mice
2024 · Shababa T. Masoud, Hoang Nguyen, et al. · Molecular Genetics and Metabolism
Supplementary Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
2023 · Landon C. Brown, Susan Halabi, et al.
Supplementary Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
2023 · Landon C. Brown, Susan Halabi, et al.
Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
2023 · Landon C. Brown, Susan Halabi, et al.
Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
2023 · Landon C. Brown, Susan Halabi, et al.
Abstract 463: Features consistent with a small-cell neuroendocrine like (SC/NE-L) transformation can be readily detected and quantified in circulating tumor cells (CTCs)
2021 · Howard I. Scher, Adam Jendrisak, et al. · Cancer Research
Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
2021 · Howard I. Scher, Andrew J. Armstrong, et al. · Journal of Clinical Oncology
Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).
2020 · Joseph Schonhoft, Audrey Gill, et al. · Journal of Clinical Oncology
Intensive and Specific Feedback Self-control of the Argonautes and MicroRNA Targeting Activity
2018 · Degeng Wang, Audrey Gill, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 24
Citation count: 460
H-index: 7
I10-index: 7
Year
Topic
Type